EGFR and central nervous system cancer: According to the fifth edition of the World Health Organization classification of tumors of the central nervous system (WHO CNS5), the primary genetic markers for gliomas are IDH mutation status, 1p19q codeletion, H3F3A alterations, ATRX gene mutations, MGMT promoter methylation status, loss of CDKN2A, and EGFR amplification, a combined gain of chromosome 7 and loss of chromosome 10, and TERT promoter pathogenic variants [29, 30].